<b>Introduction</b><b>:</b> Sodium-glucose cotransporter-2 inhibitors (SGLT2is) have proven beneficial in chronic heart failure (HF) across a wide range of left ventricular ejection fractions (LVEFs). This evidence concerns the gene SLC5A2 and congestive heart failure.